Valuation : Addex Therapeutics Ltd

Market Cap 3.44M 4.25M 3.67M 3.14M 5.91M 407M 5.93M 40.77M 15.91M 205M 15.97M 15.62M 680M P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 1.83M 2.27M 1.95M 1.67M 3.15M 217M 3.16M 21.74M 8.48M 109M 8.52M 8.33M 363M EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
43.94%
Yield 2024 *
-
Yield 2025 -
1 week-17.71%
Current month-31.43%
1 month-28.71%
3 months-36.84%
6 months-40.00%
Current year-48.01%
1 week 0.03
Extreme 0.0252
0.04
1 month 0.03
Extreme 0.0252
0.07
Current year 0.03
Extreme 0.0252
0.07
1 year 0.03
Extreme 0.0252
0.08
3 years 0.03
Extreme 0.0252
0.26
5 years 0.03
Extreme 0.0252
1.63
10 years 0.03
Extreme 0.0252
4
Manager TitleAgeSince
Chief Executive Officer 58 01/06/2013
Director of Finance/CFO 40 01/06/2017
Chief Tech/Sci/R&D Officer 69 28/11/2016
Director TitleAgeSince
Chairman 77 -
Director/Board Member 58 01/01/2015
Director/Board Member 81 12/05/2010
Date Insider Type Main position Quantity % Market Cap.
18/03/26 Other

Chief Financial Officer

602,908 0.2757%
18/03/26 Other

Founder

20,218,775 9.2469%
18/03/26 Other

Chief Technology Officer

835,976 0.3823%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-17.71%-50.00%-66.04% 4.25M
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.38%-2.72%+65.56%+95.11% 27.46B
Weighted average by Cap. -1.70%-1.06%+95.71%+133.62%

Financials

2024 2025
Net sales 410K 508K 437K 374K 705K 48.51M 707K 4.86M 1.9M 24.49M 1.91M 1.86M 81.19M 173K 214K 184K 158K 297K 20.45M 298K 2.05M 800K 10.32M 803K 786K 34.23M
Net income 7.06M 8.73M 7.53M 6.44M 12.13M 835M 12.17M 83.71M 32.66M 421M 32.79M 32.08M 1.4B -6.73M -8.33M -7.18M -6.14M -11.57M -796M -11.61M -79.83M -31.14M -402M -31.27M -30.59M -1.33B
Net Debt -3.3M -4.08M -3.52M -3.01M -5.67M -390M -5.69M -39.15M -15.27M -197M -15.33M -15M -653M -1.6M -1.99M -1.71M -1.46M -2.76M -190M -2.77M -19.03M -7.42M -95.78M -7.45M -7.29M -318M
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
28/08/26 CHF 0.0288 0.00% 1,144,616
27/08/26 CHF 0.0288 0.00% 1,334,574
26/08/26 CHF 0.0288 +11.63% 3,666,111
25/08/26 CHF 0.0258 -7.86% 4,148,380
24/08/26 CHF 0.0280 -20.00% 4,625,124
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADXN Stock